Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset FocusTEL ...

Vetter, a globally operating CDMO, has completed several important steps in the ongoing development and upcoming launch of V-OVS® next.

Clinical trials continue to be a driving force in ophthalmology, propelling the development of innovative treatments and ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...